X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ReViral brings to Pfizer a portfolio of promising therapeutic candidates, including RV521 (sisunatovir), an orally administered inhibitor designed to block fusion of the RSV virus to the host cell.
Lead Product(s): Sisunatovir
Therapeutic Area: Infections and Infectious Diseases Product Name: RV521
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $525.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition June 09, 2022
Details:
Proposed acquisition strengthens Pfizer’s capabilities in infectious disease research and development with a promising therapeutic candidates, including sisunatovir, an orally administered inhibitor designed to block fusion of the RSV virus to the host cell.
Lead Product(s): Sisunatovir
Therapeutic Area: Infections and Infectious Diseases Product Name: RV521
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $525.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition April 07, 2022
Details:
REVIRAL1 study evaluate safety, tolerability, pharmacokinetic profile, antiviral effects, and clinical effect of single and multiple oral doses of sisunatovir in healthy infants between ages of 1 and 36 months hospitalized with RSV lower respiratory tract infections.
Lead Product(s): Sisunatovir
Therapeutic Area: Infections and Infectious Diseases Product Name: RV521
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2021
Details:
Sisunatovir is ReViral’s lead small molecule for the treatment of RSV, currently in Phase 2 clinical studies in pediatric and adult immunocompromised patient populations.
Lead Product(s): Sisunatovir
Therapeutic Area: Infections and Infectious Diseases Product Name: RV521
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: LianBio
Deal Size: $119.0 million Upfront Cash: $14.0 million
Deal Type: Collaboration March 02, 2021
Details:
The proceeds from the financing will be used to support Phase 2 clinical development for sisunatovir, ReViral's wholly-owned fusion protein inhibitor, and to progress our N-protein replication inhibitor program into Phase 1.
Lead Product(s): Sisunatovir
Therapeutic Area: Infections and Infectious Diseases Product Name: RV521
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CR-CP Life Science Fund
Deal Size: $44.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing August 25, 2020
Details:
Sisunatovir is the company’s most advanced product candidate, with two international multicentre Phase 2 clinical studies recently initiated in pediatric and high-risk adult patient populations.
Lead Product(s): Sisunatovir
Therapeutic Area: Infections and Infectious Diseases Product Name: RV521
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
